Since previous reports demonstrated that the efficacy of EGFR inhibitors differed based on TME composition in NSCLC (i.e., a subset of samples with high PD-L1 and CD8 expression poorly benefitted from targeted treatment) [9], we also correlated the immunological profiles in ASPS with clinical data related to crizotinib treatment. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.